Caixin
May 26, 2022 08:41 PM
ECONOMY

In Depth: As Mass Covid Testing Becomes China’s New Normal, Debate Grows Over Who Pays

A regular nucleic acid testing mandate across the country could cost around 1.8% of GDP, economists estimate. Photo: VCG
A regular nucleic acid testing mandate across the country could cost around 1.8% of GDP, economists estimate. Photo: VCG

As China’s local governments rack up billions of yuan of health care costs to implement the country’s dynamic “zero-Covid” policy, including mass testing and vaccination campaigns, a debate is growing about where the money is coming from to pay for it all.

Testing to root out chains of transmission has been one of the government’s main weapons to fight the nation’s worst Covid-19 outbreak since early 2020. Cities where flare-ups occur require all residents to undergo nucleic acid tests, also known as PCR tests, usually every 48 hours, in order to quarantine those infected and their close contacts and to stop the virus spreading.

You've accessed an article available only to subscribers
VIEW OPTIONS
Share this article
Open WeChat and scan the QR code
NEWSLETTERS
Get our CX Daily, weekly Must-Read and China Green Bulletin newsletters delivered free to your inbox, bringing you China's top headlines.

We ‘ve added you to our subscriber list.

Manage subscription
PODCAST
Caixin Biz Roundup: China’s Covid Caseload Hits Six-Month High
00:00
00:00/00:00